banner
Trk receptor inhibitor MGCD516, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ382

Trk receptor inhibitor MGCD516, Purity ≥98%

Synonym: 1123837-84-2; Trk receptor inhibitor; MGCD516; MG516

  • CAS Number: 1123837-84-2
  • Compound CID: 25212148
img
Product Size
5 mg; 10 mg; 50 mg
Price
Datasheet
MSDS
Properties
Description
MGCD516, soluble in DMSO and ethanol and insoluble in water, blocks the activity of tropomyosin receptor kinases, which are involved in the growth and survival of neurons. It targets Axl, DDR1, DDR2, FLT3, KIT, Mer, TrkA, TrkB, VEGFR1, VEGFR2, and VEGFR3.
Molecular Weight
629.68
Molecular Formula
C33H29F2N5O4S
Targets
Axl: 1.5 nM; DDR1: 29 nM; DDR2: 0.5 nM; FLT3: 8 nM; KIT: 6 nM; Mer: 2 nM; TrkA: 5 nM; TrkB: 9 nM; VEGFR1: 6 nM; VEGFR2: 5 nM; VEGFR3: 2 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 98 mg/mL (155.63 mM); Water: Insoluble; Ethanol: 98 mg/mL
Identity
Confirmed by NMR/HPLC/MS.
Applications
MGCD516 is employed in the study of multiple kinase pathways including MET, VEGFR, and TRK, relevant for cancer therapy research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0